CPT code 0519U identifies a Proprietary Laboratory Analyses (PLA) test — SyncView® PainPlus from Phenomics Health™ Inc. — that measures plasma concentrations of 110+ drugs used to treat pain, depression, and anxiety using LC–MS/MS. Nationally, the code matters because it represents a high-complexity, manufacturer-specific laboratory service that informs medication management, adherence assessment, and safety monitoring across outpatient and reference laboratory settings. The PLA designation means the code applies only to this single commercial test, which can affect coverage determinations and payer policy development.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, typical service settings, and the landscape of payer consideration for proprietary laboratory assays. The publication summarizes benchmark topics relevant to stakeholders: coding and billing implications for a PLA code, how this test may be positioned in prior authorization and medical necessity frameworks, and clinical context for interpreting comprehensive plasma drug panels in pain, depression, and anxiety management. Data not available in the input are noted where applicable.